Cannabis Law Report

AUGUST 27, 2021

ACS Laboratory Will Grant its Safety Seal to Any Product Testing Beyond the Minimum for a Full Panel of Tests. ACS Laboratory’s Tested Safe Certified Safety Seal is a physical symbol that products passed the strictest testing guidelines in the U.S. BOCA RATON, Fla. , Aug. BOCA RATON, Fla. , Aug.

Cannabinoids 98

Cannabinoids Programs Safety Hemp 98

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JUNE 15, 2021

Drug Enforcement Administration-McAlester Resident Office and DEA Denver. The investigation was initiated by the DEA Denver office’s “Front Range Task Force” after a Chinese money laundering organization was identified that sold black market marijuana “to fund and further their criminal activities,” the sheriff office stated.

DEA 66

DEA Concentrates Safety Marijuana 66

Medicinal Genomics

FEBRUARY 8, 2023

Set at the beautiful Marriot Marco Island Resort, CannMed 23 provides an immersive forum where cannabis researchers, physicians, patients, entrepreneurs, and investors can collaborate and share their latest innovations and insights. The CannMed 23 Innovation and Investment Summit is a cannabis industry event like no other.

Wellness and Beauty 52

Wellness and Beauty Events Topical Safety 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

OCTOBER 31, 2019

“The fact is, it is still too easy and lucrative for these medical growers to jeopardize their patients by diverting patient controlled marijuana products to the illegal market.”. However, the Oregon Legislature authorized the OLCC beginning July 1, 2018 to inspect OMMP grow sites with three or more patients (13 or more plants.)

Oil 45

Oil Extraction Hash Marijuana 45

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval.

Law 105

Law Therapy Clinical Trials Research and Development 105

SpeedWeed

MARCH 21, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

THC 52

THC Business DEA Cannabinoids 52

SpeedWeed

MARCH 17, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

DEA 52

DEA Cannabinoids Research and Development THC 52

PrestoDoctor

FEBRUARY 6, 2023

Other states have a list of qualifying conditions that the patients must meet to get an MMJ. Finally, you will complete the application and get charged for your appointment (patients only pay if approved!). You must also have an Adult Patient Physician Recommendation Form dated within 30 days of the application.

Marijuana 52

Marijuana Patients Conditions Access 52

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . 30,000 patient doses) of MDMA in a four-step process beginning with a non-controlled starting material. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

SEPTEMBER 23, 2021

Tracking recent data from within the last year (following the publication of the DEA Interim Final Rule which added confusion to the delta-8 legality question), more than a dozen hospital or emergency room visits and hundreds of calls to poison control were reported. Delta-8 THC products should be kept out of the reach of children and pets.

THC 52

THC Concentrates Pets DEA 52

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Can Cannabis Improve Patient Experience Post-Surgery?” . Program between St. Vaibhav Duggal . School: Texas A&M University .

Research and Development 117

Research and Development Education Agriculture Patients 117

SpeedWeed

MARCH 21, 2021

Typically, patients may experience some of the same analgesic and antiemetic effects as Delta-9,” he adds. But there are potential safety concerns. Delta-8 isn’t mentioned by name in the 2018 Farm Bill, the DEA’s IFR or the Controlled Substances Act. A case addressing the DEA’s IFR is currently moving through the U.S.

Research and Development 52

Research and Development Hydroponic DEA Cannabinoids 52

CannaMD

SEPTEMBER 15, 2020

Current Florida medical marijuana patient? Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. Doctors and patients had to register on the Compassionate Use Registry , an online database maintained by the Florida Department of Health.

Law 126

Law Marijuana Patients Treatment 126

PrestoDoctor

JANUARY 14, 2020

Other states have a list of conditions that the patients must meet to get an MMJ. government Tribal identification card approved by the Oklahoma Department of Public Safety for identification. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Will I Be Put on a List?

Marijuana 52

Marijuana Patients Conditions Programs 52

PrestoDoctor

JANUARY 14, 2020

Other states have a list of conditions that the patients must meet to get an MMJ. government Tribal identification card approved by the Oklahoma Department of Public Safety for identification. You must have an Adult Patient Physician Recommendation Form dated within 30 days of the application. Will I Be Put on a List?

Marijuana 52

Marijuana Patients Conditions Programs 52

The Cannigma

JULY 3, 2023

They found that it could be used in sessions to promote trust and safety, helping patients to open up and process traumatic experiences. 12 From a safety perspective, there are concerns about mixing drugs increasing chances of addiction across the board, and of course unpredictable, and potentially dangerous impairment.

Research and Development 46

Research and Development Environment THC Microdosing 46

PrestoDoctor

JULY 16, 2019

In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.

Policy 40

Policy DEA Access Media 40

PrestoDoctor

JULY 16, 2019

In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.

Policy 40

Policy DEA Access Media 40

Cannabis Law Report

FEBRUARY 28, 2022

Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” 10, 2019), [link] [ [link] ]. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JUNE 4, 2021

He practiced as a British Physiotherapist for over fifteen years, running clinics that specialized in integrative pain management and injury rehabilitation, treating over 40,000 patients. Based on the way it’s produced, Delta 8-THC should be batch tested to ensure consumer safety.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

NOVEMBER 11, 2021

As detailed in our previous post , the MRTA required the CCB to “issue rules and regulations governing the home cultivation of cannabis by certified [medical marijuana] patients. no later than six months after the effective date of the MRTA.”

Programs 52

Programs Hemp Supply Chain Seed-To-Sale 52

Canna Law Blog

SEPTEMBER 6, 2023

Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.

Research and Development 113

Research and Development DEA Marijuana Pharmaceutical 113

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 59

DEA Pharmaceutical Research and Development Compliance 59

CannaMD

SEPTEMBER 10, 2020

This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented. But despite these revelations, both messaging and legalities have lagged.

Marijuana 59

Marijuana Therapy Data THC 59

Canna Law Blog

MARCH 4, 2020

According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

JUNE 10, 2021

(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

Cannabis Law Report

NOVEMBER 2, 2021

Testing for Safety: Are Impurities a Problem? Testing for Safety: Are Impurities a Problem? At present, with almost no regulation over the industry, there is a definite risk of what chemist and hemp safety expert Dr. Matthew Curran describes to Refinery29 as “kitchen chemistry.” Table of Contents. Executive Summary.

THC 96

THC CBD Legalization Vaping 96

Veriheal

JUNE 23, 2022

Outdated practices and a patchwork of laws create a legal minefield for medical patients to navigate in particular. A great example of this can be found in Pennsylvania with the case of medical cannabis patient Patrick Murphy. MMJ Patients Criminalized Despite Legality. You can read the entirety of the case appeal here.

Consumption 104

Consumption Legalization Concentrates Patients 104

Canna Law Blog

MARCH 4, 2020

According to the FDA , “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

JULY 1, 2021

Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries. Things have changed a little in the past twenty years, when the DEA gave some researchers permission to study limited amounts of certain psychedelics. POPLAR will publish original law and policy research.

Law 105

Law Research and Development Therapy DEA 105

Cannabis Law Report

MAY 24, 2022

Defendant and respondent Oakland Cannabis Buyers’ Cooperative created a medical dispensary that would serve eligible patients. Substances considered to pose the greatest risk to the public health and safety are subject to the most stringent controls and sanctions.

DEA 52

DEA History Medicine Marijuana 52

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52